The US Food and Drug Administration granted CSPC Pharmaceutical (HKG:1093) fast track designation for its CPO301 treatment for lung cancer patients, according to a Tuesday filing with the Hong Kong Exchange.

The drug is indicated for patients with recurrent or metastatic squamous non-small cell lung cancer with an overexpression of epidermal growth factor receptor despite platinum-based chemotherapy, among other therapies, the filing said.

Price (HKD): $7.04, Change: $-0.080, Percent Change: -1.12%